High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia

American Journal of Cardiology

Volumn 86, Issue 5, 2000, Pages 547-549

  Wierzbicki, Anthony S ^a   Lumb, Peter J ^a   Chik, George ^a   Crook, Martin A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CROSS-OVER STUDIES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PYRROLES; REGRESSION ANALYSIS; SIMVASTATIN; TRIGLYCERIDES;

EID: 0034284440     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)01012-2     Document Type: Article

References (20)

1. Aguilar-Salinas S.A., Barrett H., Schonfeld G. Metabolic modes of action of statins in the hyperlipoproteinemias. Atherosclerosis. 141:1998;203-207.
2. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaeffer E.J., Schectman G., Wilt T.J., Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 341:1999;410-418.
3. Sing K., Ballantyne C.M., Ferlic L., Brugada R., Cushman I., Dunn J.K., Herd J.A., Pownall H.J., Gotto A.M., Maran A.J. Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study (LCAS). Atherosclerosis. 144:1999;435-442.
4. Ballantyne C.M., Herd J.A., Ferlic L.L., Dunn J.K., Farmer J.A., Jones P.H., Schein J.R., Gotto A.M. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation. 99:1999;736-743.
5. Bakker-Arkema R., Davidson M.H., Goldstein R.J., Davignon J., Isaacson J.L., Weiss S.R., Keilson L.M., Brown V., Miller T., Shurinske L.J., Black D.M. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 275:1996;128-133.
6. Rosenson R.S., Tangney C.C. Anti-atherothrombotic properties of statins implications for cardiovascular event reduction . JAMA. 279:1998;1643-1650.
7. Wierzbicki A.S., Lumb P.J., Semra Y.K., Crook M.A. Effects of atorvastatin on plasma fibrinogen. Lancet. 351:1998;591-592.
8. Wierzbicki A.S., Lumb P.J., Semra Y.K., Chik G., Christ E.R., Crook M.A. Efficacy of atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidemias. Q J Med. 92:1999;387-389.
9. Wierzbicki A.S., Lumb P.J., Chik G., Crook M.A. Comparison of treatment with 80mg of atorvastatin and 80mg of simvastatin in patients with familial hypercholesterolemia. Int J Clin Practice. 53:1999;609-611.
10. Stein E.A., Lane M., Laszarewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 81:1998;66B-69B.
11. Crouse J.R., Frohlich J., Ose L., Mercuri M., Tobert J.A. Effects of high dose of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-1. Am J Cardiol. 82:1999;1476-1477.
12. Nestel P., Simons L., Barter P. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipidaemia prediction of response by baseline lipids, apoE genotype, lipoprotein (a) and insulin . Atherosclerosis. 128:1997;231-239.
13. Leitersdorf E. Gender-related response to fluvastatin in patients with familial hypercholesterolemia. Drugs. 47:(suppl 2):1994;54-58.
14. Heath K.E., Gudnason V., Humphries S.E., Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 143:1999;41-54.
15. Couture P., Brun L.D., Szots F., Lleivere M., Gaudet D., Depres J.P., Simard J., Lupien P.J., Gagne C. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 18:1998;1007-1012.
16. Leren T.P., Hjermann I. Is responsiveness to lovastatin in familial hypercholesterolemia heterozygotes influenced by the specific mutation in the low-density lipoprotein receptor gene? Eur J Clin Invest. 25:1995;967-973.
17. Jeener M., September W., Graadt van Roggen F., de Villiers W., Seftel H., Marais D. Influence of specific specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaaner patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 98:1993;51-58.
18. Jukema J.W., van Boven A.J., Groenmeijer B., Zwinderman A.H., Reiber J.H., Bruschke A.V., Henneman J.A., Moelhoek G.P., Bruin T., Jansen H., Gagne E., Hayden M.R., Kastelein J.J. The Asp9Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study group. Circulation. 94:1996;1913-1918.
19. Kuivenhoven J.A., Jukema J.W., Zwinderman A.H., de Knijff P., McPherson R., Bruschke A.U., Lie K.I., Kastelein J.J. The role of a common variant of the cholesterol ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study (REGRESS). N Engl J Med. 338:1998;86-93.
20. Nair D.P., Papadkis J.A., Jagroop I.A., Mikhailidis D.P., Winder A.F. Statins and fibrinogen. Lancet. 351:1998;1430.